JP2016527225A5 - - Google Patents

Download PDF

Info

Publication number
JP2016527225A5
JP2016527225A5 JP2016526580A JP2016526580A JP2016527225A5 JP 2016527225 A5 JP2016527225 A5 JP 2016527225A5 JP 2016526580 A JP2016526580 A JP 2016526580A JP 2016526580 A JP2016526580 A JP 2016526580A JP 2016527225 A5 JP2016527225 A5 JP 2016527225A5
Authority
JP
Japan
Prior art keywords
antibody
kabat
seq
upa
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016526580A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016527225A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/065136 external-priority patent/WO2015007727A1/en
Publication of JP2016527225A publication Critical patent/JP2016527225A/ja
Publication of JP2016527225A5 publication Critical patent/JP2016527225A5/ja
Withdrawn legal-status Critical Current

Links

JP2016526580A 2013-07-15 2014-07-15 ウロキナーゼ型プラスミノーゲン活性化因子に結合する抗体 Withdrawn JP2016527225A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13176519.0 2013-07-15
EP13176519 2013-07-15
US201361847664P 2013-07-18 2013-07-18
US61/847,664 2013-07-18
PCT/EP2014/065136 WO2015007727A1 (en) 2013-07-15 2014-07-15 Antibodies that bind urokinase plasminogen activator

Publications (2)

Publication Number Publication Date
JP2016527225A JP2016527225A (ja) 2016-09-08
JP2016527225A5 true JP2016527225A5 (enExample) 2017-08-10

Family

ID=48783103

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016526580A Withdrawn JP2016527225A (ja) 2013-07-15 2014-07-15 ウロキナーゼ型プラスミノーゲン活性化因子に結合する抗体

Country Status (6)

Country Link
US (1) US9908944B2 (enExample)
EP (1) EP3022229A1 (enExample)
JP (1) JP2016527225A (enExample)
CN (1) CN105612183A (enExample)
TW (1) TW201536810A (enExample)
WO (1) WO2015007727A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
ES2955074T3 (es) 2017-02-20 2023-11-28 Dragonfly Therapeutics Inc Proteínas que se unen a HER2, NKG2D Y CD16
EP3459974B1 (en) * 2017-09-21 2025-02-19 Guy L. Reed Specific plasmin inactivation by anticatalytic antibody
CA3090236A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor
KR102832460B1 (ko) 2018-02-20 2025-07-11 드래곤플라이 쎄라퓨틱스, 인크. Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법
MX2021001527A (es) 2018-08-08 2021-06-15 Dragonfly Therapeutics Inc Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor.
MA53293A (fr) 2018-08-08 2021-11-17 Dragonfly Therapeutics Inc Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation
EA202091888A1 (ru) * 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
CN111253486B (zh) * 2018-09-27 2023-09-29 再鼎医药(上海)有限公司 抗pd-1抗体及其用途
CN110343665B (zh) * 2019-05-05 2023-07-14 吉林大学 一种car-t细胞及其应用
US20230220112A1 (en) * 2019-10-28 2023-07-13 Monash University Antibodies for binding plasmin
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
CN114917329B (zh) * 2021-02-11 2023-07-21 兰州大学第二医院 抗cd87抗体与抗pd1抗体联合治疗胃癌
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
JP2025168320A (ja) * 2024-04-26 2025-11-07 イーライ リリー アンド カンパニー タンパク質チロシンキナーゼ7抗体及び抗体-薬物コンジュゲート

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453269A (en) 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
TW212184B (enExample) 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
US8062637B2 (en) 2000-05-08 2011-11-22 Morphosys Ag Methods of ameliorating inflammatory disease using an uPA antagonist
EP1406652A2 (en) 2001-07-10 2004-04-14 Omnio AB Novel drug targets for arthritis
WO2003057881A1 (en) * 2001-12-28 2003-07-17 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
WO2005048822A2 (en) 2003-11-18 2005-06-02 Attenuon Llc Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
EP1814914A2 (en) 2004-10-29 2007-08-08 The Regents of the University of Colorado Antibodies that bind urokinase-type plasminogen activator and epitopes therefor
EP1876236B9 (en) * 2005-04-08 2015-02-25 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
JP5908972B2 (ja) * 2011-04-07 2016-04-26 アムジエン・インコーポレーテツド 新規な抗原結合タンパク質

Similar Documents

Publication Publication Date Title
JP2016527225A5 (enExample)
JP2018510636A5 (enExample)
JP2019122405A5 (enExample)
RU2017114341A (ru) Антитела к pd-l1, связывающие pd-l1 собаки
JP2016512551A5 (enExample)
HRP20201928T1 (hr) Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1
JP2010536384A5 (enExample)
JP2017528476A5 (enExample)
PH12020551173A1 (en) Anti-pd-l1 antibodies and uses thereof
PE20181051A1 (es) Anticuerpo anti-epha4
JP2013198490A5 (enExample)
RU2017137010A (ru) Анти-сеасам6 антитела и их применения
JP2013091655A5 (enExample)
NZ585559A (en) Humanized antibodies against tl1a
PE20141186A1 (es) Proteinas de union al tnf-alfa
PE20120835A1 (es) Anticuerpos anti-tnf-alfa y sus usos
JP2017052784A5 (enExample)
JP2017534577A5 (enExample)
RU2017134495A (ru) Антитела к альфа-рецептору собачьего интерлейкина-4
NZ596042A (en) Humanized anti-factor d antibodies
AR065506A1 (es) Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades
JP2018527903A5 (enExample)
WO2006103100A3 (en) Antibodies against ccr5 and uses thereof
JP2014512809A5 (enExample)
JP2016533763A5 (ja) ヒトpd−1に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物